Compare NVR & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVR | RPRX |
|---|---|---|
| Founded | 1980 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.9B | 19.5B |
| IPO Year | 1995 | 2020 |
| Metric | NVR | RPRX |
|---|---|---|
| Price | $6,460.51 | $49.69 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $7,157.80 | $51.40 |
| AVG Volume (30 Days) | 15.5K | ★ 2.5M |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 1.90% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 436.55 | 1.78 |
| Revenue | ★ $10,323,959,000.00 | $2,378,193,000.00 |
| Revenue This Year | N/A | $38.63 |
| Revenue Next Year | $6.60 | $4.73 |
| P/E Ratio | ★ $14.97 | $27.69 |
| Revenue Growth | N/A | ★ 5.06 |
| 52 Week Low | $6,301.03 | $31.97 |
| 52 Week High | $8,618.28 | $50.08 |
| Indicator | NVR | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 40.68 | 63.01 |
| Support Level | $6,301.03 | $35.34 |
| Resistance Level | $7,778.36 | $50.08 |
| Average True Range (ATR) | 191.57 | 0.89 |
| MACD | -14.68 | 0.01 |
| Stochastic Oscillator | 7.44 | 88.17 |
NVR Inc is engaged in the construction and sale of residential properties, including single-family detached homes, townhomes, and condominium buildings, all of which are built on a pre-sold basis. Additionally, the company provides related services through its mortgage banking and title services businesses. Its business segments are Homebuilding and Mortgage Banking. Its geographical segments include the Mid Atlantic, the North East, the Mid East, and the South East regions of America. The majority of the company's revenue is derived from the Homebuilding Mid Atlantic segment, which includes homebuilding operations that construct and sell single-family detached homes, townhomes and condominiums in Maryland, Virginia, West Virginia, Delaware and Washington, D.C. regions.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.